Saudi Arabia Human Insulin Market Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Indication (Type I Diabetes, Type Il Diabetes), By Route of Administration (Subcutaneous, Nasal, Intravenous, Transdermal, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-lo
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationSaudi Arabia Human Insulin Market Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Indication (Type I Diabetes, Type Il Diabetes), By Route of Administration (Subcutaneous, Nasal, Intravenous, Transdermal, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-lo
| Forecast Period | 2024-2028 |
| Market Size (2022) | 0.31 billion |
| CAGR (2023-2028) | 1.68% |
| Fastest Growing Segment | Segment |
| Largest Market | Northern & Central |
Market Overview
Saudi Arabia Human Insulin Market has valued at USD 0.31 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 1.68 % through 2028. Human insulin is a peptide hormone that plays a crucial role in regulating blood sugar levels in the human body. It is produced by the beta cells of the pancreas, specifically in the Islets of Langerhans, and is essential for the uptake and utilization of glucose by the body's cells. Human insulin is a protein hormone composed of 51 amino acids organized into two chainsan A-chain with 21 amino acids and a B-chain with 30 amino acids. These two chains are held together by disulfide bonds. Human insulin is synthesized within the pancreas as a precursor molecule known as proinsulin. Proinsulin is later processed to produce the active insulin molecule. During this processing, a portion of the proinsulin molecule, called the C-peptide, is cleaved, and released into the bloodstream along with the active insulin. The primary role of insulin is to regulate blood sugar (glucose) levels. It acts as a key that allows glucose to enter cells, where it can be used for energy production. When blood sugar levels rise, typically after eating, the pancreas releases insulin to facilitate the uptake of glucose into cells, thereby reducing blood sugar levels.
An aging population is more prone to diabetes, particularly Type II diabetes. As the demographic structure of the country changes, the market for insulin expands. Urbanization is associated with lifestyle changes that increase the risk of diabetes. Saudi Arabia's ongoing urbanization drives the need for diabetes management and insulin therapy. Greater awareness about the importance of early diabetes diagnosis and management encourages more people to seek medical care and insulin therapy. Advances in insulin delivery systems and monitoring technologies improve the convenience and effectiveness of insulin therapy, encouraging more people to use insulin. Expanding health insurance coverage and reimbursement policies for insulin and related supplies can reduce the financial burden on patients and promote insulin use. Healthcare providers' recommendations and prescriptions of insulin for diabetes management are a significant driver. The trust and advice of medical professional’s influence patient choices.
Key Market Drivers
Technological Advancements
Insulin pens have become a popular choice for insulin delivery due to their ease of use and convenience. These devices offer accurate dosing, discreetness, and the ability to carry them anywhere. Some insulin pens are also equipped with memory features, which allow patients and healthcare providers to track dosages and adherence. Insulin pumps are wearable devices that continuously deliver insulin, providing a more stable and precise method of insulin administration. They are programmable and can deliver both basal and bolus doses, mimicking the body's natural insulin production. Continuous Glucose Monitoring (CGM) Systems continuously monitor blood glucose levels and provide real-time data to patients. They allow for better insulin dose adjustments, reducing the risk of hypoglycemia and hyperglycemia. Closed-loop systems combine CGM and insulin pump technology to automate insulin delivery in response to real-time glucose data. This "artificial pancreas" concept reduces the burden of managing diabetes and improves glycemic control.
Smart pens are connected devices that record and transmit dose information to a smartphone app or cloud-based platform. This technology helps patients and healthcare providers track insulin usage and adherence over time. Inhalable insulin offers an alternative to injectable insulin. Patients inhale a dry powder insulin formulation, providing a non-invasive method of insulin delivery. Long-acting insulin analogs, such as insulin glargine and insulin detemir, have extended durations of action, allowing for once-daily or even less frequent dosing. This reduces the need for multiple daily injections. Researchers are working on developing oral insulin formulations, which would be easier to administer for some patients. These formulations need to overcome challenges related to absorption and effectiveness.
Telemedicine and digital health platforms offer remote monitoring and consultation for diabetes management. These technologies provide patients with convenient access to healthcare providers and empower them to manage their condition more effectively. Advances in biotechnology have led to the development of biosimilar insulins that are similar in structure and function to human insulin. These biosimilar insulins can provide cost-effective alternatives to traditional human insulins. Advancements in genomics and personalized medicine allow for more individualized diabetes treatment plans, considering a person's genetic profile, lifestyle, and responsiveness to different types of insulin. This factor will help in the development of the Saudi Arabia Human Insulin Market.
Increasing Awareness
Greater awareness about the signs and risk factors of diabetes encourages individuals to seek medical attention and get screened for diabetes. Early diagnosis is key to timely intervention and appropriate treatment, including the use of insulin when necessary. Diabetes prevention programs often include lifestyle modifications and education on healthy eating and physical activity. By reducing the incidence of diabetes, these programs can indirectly limit the demand for insulin. Informed patients are more likely to actively participate in their healthcare and adhere to prescribed treatment regimens, including insulin therapy. Knowledge about the importance of insulin can lead to better self-management of the condition.
Greater awareness can help reduce the stigma associated with diabetes and insulin use. This, in turn, encourages more individuals to consider insulin when it is medically indicated. Educated patients are more likely to understand the benefits of insulin therapy and the potential risks of non-compliance. They are, therefore, more likely to adhere to their insulin regimens as prescribed by healthcare providers. Increased awareness often leads to the formation of patient advocacy groups and support networks. These organizations can provide valuable information and resources to individuals with diabetes, further contributing to their understanding and proactive approach to insulin therapy.
Awareness campaigns target healthcare professionals as well, ensuring that they are well-informed about the latest guidelines and recommendations for diabetes management, including the use of insulin when necessary. Government health departments and agencies may launch public awareness campaigns as part of their efforts to combat diabetes. These initiatives can lead to greater recognition of the condition and its management. Community-based educational programs and events can reach underserved populations and help them access essential information about diabetes, insulin therapy, and found at resources. This factor will pace up the demand of the Saudi Arabia Human Insulin Market.
Rising Urbanization
Urban areas often witness significant lifestyle changes, including sedentary behavior and dietary shifts. These changes can contribute to an increased risk of developing diabetes, particularly Type 2 diabetes, which may necessitate insulin therapy. Urban populations tend to have greater access to high-calorie, processed foods that are linked to obesity and diabetes. These dietary habits can lead to a higher prevalence of diabetes, increasing the demand for insulin. The demands of urban living can lead to increased stress, which may have an impact on blood sugar levels. Stress can be a contributing factor to the development and management of diabetes, potentially leading to the need for insulin.
Urban environments can expose individuals to higher levels of air pollution and other environmental factors that have been associated with an increased risk of diabetes. Urban areas may have limited opportunities for physical activity, and desk-bound jobs are common. A lack of physical activity is a risk factor for diabetes, contributing to the need for insulin therapy in urban populations. Urban areas typically have better access to healthcare facilities, including clinics and hospitals. This improved access may lead to more diabetes diagnoses and insulin prescriptions. Urban areas are often more densely populated, resulting in a higher number of individuals at risk for diabetes. This increased population density can lead to a larger pool of potential diabetes patients.
Urban environments are more likely to have greater access to health awareness and education programs. These programs may encourage individuals to get screened for diabetes and seek early treatment, which could include insulin. Urban jobs often involve shift work and irregular schedules, which can disrupt eating and sleeping patterns. These disruptions can impact blood sugar control, potentially necessitating insulin therapy. Urban residents may have greater access to digital devices and screen time, which can contribute to a more sedentary lifestyle and affect diabetes risk. Urban areas tend to have a high density of fast-food outlets, which can promote unhealthy eating habits and obesity, both of which are risk factors for diabetes. This factor will accelerate the demand of the Saudi Arabia Human Insulin Market.
Key Market Challenges
Quality and Safety
Ensuring that human insulin products comply with national and international regulations and quality standards is an ongoing challenge. Regulatory authorities, such as the Saudi Food and Drug Authority (SFDA), play a crucial role in monitoring and enforcing these standards. Counterfeit or substandard insulin products can pose significant safety risks to patients. Regulators, manufacturers, and distributors need to work together to combat counterfeit insulin and protect patients. Proper storage and handling of insulin products are essential to maintaining their quality and safety. Variations in temperature and mishandling can compromise the effectiveness of insulin, potentially endangering patients' lives. The insulin supply chain from manufacturing to patient use is complex and includes multiple stakeholders. Ensuring the integrity of the supply chain is vital to prevent contamination or tampering with insulin products. Occasionally, insulin products may need to be recalled due to quality or safety issues. Managing these recalls and preventing patient harm is a challenge. Manufacturers must maintain strict quality control processes throughout the production of insulin. This includes testing the purity and potency of the insulin to ensure that it meets the required standards. Monitoring and reporting adverse events associated with insulin use are essential for identifying safety concerns and taking corrective actions.
Market Competition
Intense competition among pharmaceutical companies can lead to price pressure. While this can make insulin more affordable for patients, it may also affect the profitability of insulin manufacturers, potentially impacting research, and development efforts. To remain competitive, some manufacturers may cut costs, potentially compromising the quality and safety of insulin products. Regulatory authorities must ensure that all insulin products meet stringent quality standards. Gaining and maintaining market share is challenging. Established insulin manufacturers may face competition from newer entrants or biosimilar products. This competition can impact their market share and profitability. Competition encourages companies to innovate and develop new insulin products. However, keeping up with the latest technological advancements and staying ahead of competitors can be a significant challenge for manufacturers. Entering the insulin market is not easy. Manufacturers must meet regulatory requirements, ensure product quality, and invest in research and development. These barriers can be challenging for new entrants. Competition can intensify in the distribution of insulin products. Ensuring equitable access to insulin across the country, including remote areas, is a challenge for both manufacturers and distributors.
Key Market Trends
Biopharmaceutical Developments
Biopharmaceutical companies are increasingly focused on developing insulin products using biotechnological methods. These products, often referred to as recombinant human insulin or insulin analogs, are produced through genetic engineering techniques using bacteria, yeast, or mammalian cells. This results in insulin that closely mimics the structure and function of human insulin. Biotechnologically derived insulin products tend to have higher purity and potency compared to insulin extracted from animal sources. This can result in improved glycemic control and reduced risk of adverse reactions. Advances in biotechnology have enabled the development of customized insulin analogs that can better match individual patient needs. These analogs offer more flexible treatment options, allowing healthcare providers to tailor insulin therapy to specific patient profiles. Biopharmaceutical developments have led to the creation of long-acting and ultra-long-acting insulin analogs, such as insulin glargine and insulin degludec. These insulins provide a basal level of insulin action for extended periods, reducing the need for multiple daily injections. Rapid-acting insulin analogs, such as insulin lispro and insulin aspart, offer faster onset and shorter duration of action, allowing for better post-meal blood sugar control. The development of biosimilar insulins, which are highly like existing insulin products, provides more affordable alternatives for patients while maintaining comparable safety and efficacy.
Segmental Insights
Indication Insights
In 2022, the Saudi Arabia Human Insulin Market largest share was held by Type Il Diabetes segment and is predicted to continue expanding over the coming years.
Onset Time Insights
In 2022, the Saudi Arabia Human Insulin Market largest share was held by Intermediate Acting segment and is predicted to continue expanding over the coming years.
Products Insights
In 2022, the Saudi Arabia Human Insulin Market largest share was held by
Regional Insights
The Northern & Central region dominates the Saudi Arabia Human Insulin Market in 2022.
Recent Developments
- In July 2022, during aceremonial visit with United States of America President Joe Biden, theleadership of Digital Diagnostics, the creator of IDx-DR, the first-everFDA-cleared, fully autonomous AI system for diagnosing diabetic retinopathy,signed a memorandum of understanding (MOU) with the Ministry of Investment ofthe Kingdom of Saudi Arabia. Through this MOU, Digital Diagnostics and theKingdom of Saudi Arabia aim to explore potential collaboration in the fields ofmedical services, medical technology, and digital health, involving asignificant economic investment. IDx-DR, the product developed by DigitalDiagnostics, streamlines the diabetic eye examination process during theinitial patient encounter, enabling early detection of diabetic retinopathy.This diabetic eye examination not only enhances patient outcomes but alsoresults in a lifetime cost savings of $1 million per patient.
Key Market Players
- Novo Nordisk Saudi Arabia
- Sanofi Saudi Arabia
- Baxter International SaudiArabia
- B Braun Saudi Arabia
- Eli Lilly, and CompanySaudi Arabia
- Pfizer Saudi Arabia
| By Indication | By Type | By Onset Time | By Products | By Region | By Region |
|
|
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy